ClinicalTrials.gg
RecruitingNCT06844032Updated Apr 17, 2026

Predictors of Poor Prognosis in HFpEF

An observational study in HFpEF, sponsored by National Medical Research Center for Cardiology, Ministry of Health of Russian Federation. Recruiting at 1 site in Russia. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-04-17.

Sponsored by National Medical Research Center for Cardiology, Ministry of Health of Russian Federation · Observational

From the registry’s dates

  • Started Jan 2022; still recruiting 4 years 9 months later.
Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
500
Ages
40 Years and older
Sex
All
01

Study summary

Patients with HFpEF who have undergone meticulous clinical and instrumental evaluation (including diastolic exercise testing) between 2013 and 2020, will be followed up for at least 3 years.

Read the detailed description

Heart failure with preserved ejection fraction (HFpEF) is a serious condition with an unfavorable prognosis.

The investigators aimed to evaluate in patients with HFpEF:

  • the prognostic significance of standard resting hemodynamic parameters compared to key cardiac reserves;
  • the prognostic significance of clinical parameters (sex, age, NYHA class, extra-cardiac diseases, therapy);
  • the prognostic significance of biological markers of hemodynamic stress and biomarkers of inflammation and fibrosis;
  • to identify independent predictors of adverse prognosis of HFpEF.
02

Conditions studied

  • HFpEF

Keywords

  • HFpEF
  • HF
  • diastolic dysfunction
  • left ventricle (LV) filling pressures
  • left ventricular hypertrophy
  • cardiac reserves
  • myocardial fibrosis
03

In context

Hypertrophy, Left Ventricular

162 studies on the registry are indexed under Hypertrophy, Left Ventricular; 28 are open to participants now.

This study's planned enrollment of 500 is above the median of 198 across 60 observational studies indexed under Hypertrophy, Left Ventricular.

Browse Hypertrophy, Left Ventricular studies →

Lead sponsor

National Medical Research Center for Cardiology, Ministry of Health of Russian Federation is the lead sponsor of 20 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Outpatients with HFpEF who underwent meticulous clinical evaluation between 2013 and 2020 at the National Medical Research Centre for Cardiology (Moscow, Russian Federation)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed and data ;
  2. (NYHA) class II-III heart failure;
  3. > 50%;
  4. Elevated LV filling pressures assessed by echocardiography at rest or at peak exercise.

Exclusion criteria

Exclusion Criteria:

  1. Evidence of myocardial ischemia during stress echocardiography;
  2. Significant lesions of the main coronary arteries;
  3. Genetic forms of HFpEF (HCM, amyloidosis, Fabry disease, glycogen storage diseases etc.);
  4. Peripartum cardiomyopathy, chemotherapy-induced cardiomyopathy, viral myocarditis, isolated right-sided HF without left-sided structural disease, constrictive pericarditis, significant pericardial effusion;
  5. Significant lung disease (severe lung disease requiring home oxygen or chronic oral therapy);
  6. Primary pulmonary artery hypertension;
  7. Significant left-sided structural valve disease;
  8. Anemia ( \< 100 g/L);
  9. Impaired renal function, defined as estimated (eGFR) \<30 mL/min/1.73 m2 (CKD-EPI);
  10. Non-cardiac conditions that complicate/exclude participation in the study;
  11. Exacerbation of heart failure less than 3 months prior to study entry.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • with primary outcome

    Patients with HFpEF who experienced primary outcome (were hospitalized for HF or died)

  • without primary outcome

    Patients with HFpEF who survived without hospitalization for HF

06

What researchers measure

Primary outcomes

  1. Hospitalization for exacerbation of HF

    Time frame: From enrollment to August 2026

  2. All-cause mortality

    Time frame: From enrollment to August 2026

07

Study locations

1 of 1 sites recruiting
  • Federal State Budgetary Institution NATIONAL MEDICAL RESEARCH CENTRE OF CARDIOLOGY NAMED AFTER ACADEMICIAN E.I.CHAZOV. of the Ministry of Health of the Russian Federation
    Moscow, 121552, Russia
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06844032
Lead sponsor
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Responsible party
Sponsor
First posted
Feb 25, 2025
Start date
Jan 31, 2022
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Apr 17, 2026

Study contacts

Artem G Ovchinnikov, MD, PhD, DSc
Contact
artcardio@mail.ru
+74954146612

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion